Article PDF first page preview

First page of Upper urinary tract urothelial carcinoma diagnosis effect on life expectancy relative to population-based controls: a retrospective analysis

Purpose: To exam five-year overall survival (OS) of upper urinary tract urothelial carcinoma (UTUC) patients versus age- and sex-matched population-based controls. Methods: Within Surveillance, Epidemiology, and End Results database (2004-2020), we identified newly diagnosed (2004-2015) UTUC patients. Relying on Social Security Administration Life Tables (2004-2020) age- and sex- matched population-based controls were simulated (Monte Carlo simulation). Results: Of 10,140 UTUC patients, 3,984 (39%) exhibited localized, 4,904 (49%) locally advanced, and 1,252 (12%) metastatic stage. At five years of follow-up, the OS rate was 41 versus 78% (Δ 37%) in UTUC patients versus controls. According to stage, OS difference was greatest in metastatic stage (4 versus 75%; Δ 71%), followed by locally advanced (36 versus 78%; Δ 42%) and localized stage (58 versus 78%; Δ 20%). At five years of follow-up, CSM rate was 44% and OCM rate was 16%. According to stage, CSM and OCM rates were 88 and 7% in metastatic, 49 and 15% in locally advanced, and 22 and 19% in localized stage UTUC patients. Conclusion: UTUC patients may experience worse OS compared to population-based controls. The most pronounced differences in five-year OS were recorded in metastatic and locally advanced stage, suggesting a potentially substantial impact of UTUC on patients’ life expectancy.

Journal Section:
Research Article
This content is only available via PDF.
The Author(s). Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution 4.0 International License (CC BY). Usage, derivative works and distribution are permitted provided that proper credit is given to the author and the original publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
This work is licensed under a Creative Commons Attribution 4.0 International License .
Attribution